Vadim Koshkin, MD

Title(s)Assistant Professor, Medicine
SchoolSchool of Medicine
Address550 16th. Street
San Francisco CA 94158
Phone--
ORCID ORCID Icon0000-0003-2277-8668 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of Pennsylvania, Philadelphia, PABA05/2007Cognitive Science
    University of Chicago, Pritzker School of Medicine, Chicago, ILMD06/2012Medicine
    University of Michigan, Ann Arbor, MI06/2015Internal Medicine Residency
    Cleveland Clinic, Cleveland, OH06/2018Hematology/Oncology Fellowship
    Collapse Awards and Honors
    Prostate Cancer Foundation2021  - 2024Young Investigator Award
    National Cancer Institute 2020  - 2022NIH Loan Repayment Program (LRP) Grant
    Hellen Diller Family Comprehensive Cancer Center at UCSF2019  - 2020Junior Clinical Investigator Award
    Bladder Cancer Advocacy Network (BCAN)2017John Quale Travel Fellowship Award
    Kidney Cancer Association2017Young Investigator Abstract Award
    Conquer Cancer Foundation2017Abstract Merit Award
    AACR/ASCO2016Methods in Clinical Cancer Research Workshop Participant
    Conquer Cancer Foundation 2015Abstract Merit Award

    Collapse Overview 
    Collapse Overview
    I am a genitourinary medical oncologist and in this capacity I specialize in caring for patients with bladder, prostate, kidney and testicular cancers. My focus is in clinical and translational research in bladder and prostate cancers, in particular the design and implementation of clinical trials for patients with these malignancies and the discovery and validation of novel biomarkers and treatment targets.

    Collapse Research 
    Collapse Research Activities and Funding
    Using CDK 4/6 Inhibition to Augment PSMA Expression in Advanced Prostate Cancer and Enhance Clinical Responses to PSMA-Targeted Radioligand Therapy
    Prostate Cancer Foundation 20YOUN07Jan 4, 2021 - Jan 3, 2024
    Role: Principal Investigator
    Role Description: First in human clinical trial of CDK4 inhibitor followed by 177Lu-PSMA-617 in patients with advanced prostate cancer.

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Featured Publications

    Collapse Featured Content 
    Collapse Twitter

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19. JAMA Oncol. 2021 Jun 17. Thompson MA, Henderson JP, Shah PK, Rubinstein SM, Joyner MJ, Choueiri TK, Flora DB, Griffiths EA, Gulati AP, Hwang C, Koshkin VS, Papadopoulos EB, Robilotti EV, Su CT, Wulff-Burchfield EM, Xie Z, Yu PP, Mishra S, Senefeld JW, Shah DP, Warner JL, COVID-19 and Cancer Consortium . PMID: 34137799.
      View in: PubMed   Mentions:    Fields:    
    2. Heterogeneity in NECTIN4 expression across molecular subtypes of urothelial cancer mediates sensitivity to enfortumab vedotin. Clin Cancer Res. 2021 Jun 09. Chu CE, Sjöström M, Egusa EA, Gibb EA, Badura ML, Zhu J, Koshkin VS, Stohr BA, Meng MV, Pruthi RS, Friedlander TW, Lotan Y, Black PC, Porten SP, Feng FY, Chou J. PMID: 34108177.
      View in: PubMed   Mentions: 1     Fields:    
    3. TERT promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor. J Immunother Cancer. 2021 May; 9(5). de Kouchkovsky I, Zhang L, Philip EJ, Wright F, Kim DM, Natesan D, Kwon D, Ho H, Ho S, Chan E, Porten SP, Wong AC, Desai A, Huang FW, Chou J, Oh DY, Pruthi RS, Fong L, Small EJ, Friedlander TW, Koshkin V. PMID: 33980590.
      View in: PubMed   Mentions:    Fields:    
    4. Reply to R. Kebudi et al. JCO Oncol Pract. 2021 Apr 21; OP2100105. Tsu-Yu Wu J, Kwon DH, Glover M, Henry S, Wood D, Rubin D, Koshkin V, Schapira L, Shah SA. PMID: 33881937.
      View in: PubMed   Mentions:
    5. Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium. Ann Oncol. 2021 06; 32(6):787-800. Grivas P, Khaki AR, Wise-Draper TM, French B, Hennessy C, Hsu CY, Shyr Y, Li X, Choueiri TK, Painter CA, Peters S, Rini BI, Thompson MA, Mishra S, Rivera DR, Acoba JD, Abidi MZ, Bakouny Z, Bashir B, Bekaii-Saab T, Berg S, Bernicker EH, Bilen MA, Bindal P, Bishnoi R, Bouganim N, Bowles DW, Cabal A, Caimi PF, Chism DD, Crowell J, Curran C, Desai A, Dixon B, Doroshow DB, Durbin EB, Elkrief A, Farmakiotis D, Fazio A, Fecher LA, Flora DB, Friese CR, Fu J, Gadgeel SM, Galsky MD, Gill DM, Glover MJ, Goyal S, Grover P, Gulati S, Gupta S, Halabi S, Halfdanarson TR, Halmos B, Hausrath DJ, Hawley JE, Hsu E, Huynh-Le M, Hwang C, Jani C, Jayaraj A, Johnson DB, Kasi A, Khan H, Koshkin VS, Kuderer NM, Kwon DH, Lammers PE, Li A, Loaiza-Bonilla A, Low CA, Lustberg MB, Lyman GH, McKay RR, McNair C, Menon H, Mesa RA, Mico V, Mundt D, Nagaraj G, Nakasone ES, Nakayama J, Nizam A, Nock NL, Park C, Patel JM, Patel KG, Peddi P, Pennell NA, Piper-Vallillo AJ, Puc M, Ravindranathan D, Reeves ME, Reuben DY, Rosenstein L, Rosovsky RP, Rubinstein SM, Salazar M, Schmidt AL, Schwartz GK, Shah MR, Shah SA, Shah C, Shaya JA, Singh SRK, Smits M, Stockerl-Goldstein KE, Stover DG, Streckfuss M, Subbiah S, Tachiki L, Tadesse E, Thakkar A, Tucker MD, Verma AK, Vinh DC, Weiss M, Wu JT, Wulff-Burchfield E, Xie Z, Yu PP, Zhang T, Zhou AY, Zhu H, Zubiri L, Shah DP, Warner JL, Lopes G. PMID: 33746047.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansPHPublic Health
    6. Differential treatment outcomes in BRCA1/2-, CDK12-, and ATM-mutated metastatic castration-resistant prostate cancer. Cancer. 2021 Jun 15; 127(12):1965-1973. Kwon DH, Chou J, Yip SM, Reimers MA, Zhang L, Wright F, Dhawan MS, Borno HT, Desai A, Aggarwal RR, Wyatt AW, Small EJ, Alva AS, Chi KN, Feng FY, Koshkin VS. PMID: 33690902.
      View in: PubMed   Mentions:    Fields:    
    7. Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes. BJU Int. 2021 Feb 08. Esagian SM, Khaki AR, Diamantopoulos LN, Carril-Ajuria L, Castellano D, De Kouchkovsky I, Park JJ, Alva A, Bilen MA, Stewart TF, McKay RR, Santos VS, Agarwal N, Jain J, Zakharia Y, Morales-Barrera R, Devitt ME, Nelson A, Hoimes CJ, Shreck E, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Rodriguez-Vida A, Drakaki A, Liu S, Kumar V, Lythgoe MP, Pinato DJ, Murgic J, Fröbe A, Joshi M, Isaacsson Velho P, Hahn N, Alonso Buznego L, Duran I, Moses M, Barata P, Galsky MD, Sonpavde G, Yu EY, Msaouel P, Koshkin VS, Grivas P. PMID: 33556233.
      View in: PubMed   Mentions:    Fields:    
    8. Update on First-Line Combination Treatment Approaches in Metastatic Clear-Cell Renal Cell Carcinoma. Curr Treat Options Oncol. 2021 Jan 12; 22(2):15. Christensen BR, Hajja YM, Koshkin V, Barata PC. PMID: 33438115.
      View in: PubMed   Mentions:    Fields:    
    9. A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors. Eur Urol Oncol. 2021 Jun; 4(3):464-472. Khaki AR, Li A, Diamantopoulos LN, Miller NJ, Carril-Ajuria L, Castellano D, De Kouchkovsky I, Koshkin V, Park J, Alva A, Bilen MA, Stewart T, Santos V, Agarwal N, Jain J, Zakharia Y, Morales-Barrera R, Devitt M, Nelson A, Hoimes CJ, Shreck E, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Rodriguez-Vida A, Drakaki A, Liu S, Kumar V, Lythgoe MP, Pinato DJ, Murgic J, Fröbe A, Joshi M, Isaacsson Velho P, Hahn N, Alonso Buznego L, Duran I, Moses M, Barata P, Galsky MD, Sonpavde G, Yu EY, Shankaran V, Lyman GH, Grivas P. PMID: 33423945.
      View in: PubMed   Mentions:    Fields:    
    10. Changes in Cancer Management due to COVID-19 Illness in Patients with Cancer in Northern California. JCO Oncol Pract. 2021 Mar; 17(3):e377-e385. Wu JT, Kwon DH, Glover MJ, Henry S, Wood D, Rubin DL, Koshkin VS, Schapira L, Shah SA. PMID: 33332170.
      View in: PubMed   Mentions:
    11. Evaluating determinants of receipt of molecular imaging in biochemical recurrent prostate cancer. Cancer Med. 2021 01; 10(1):62-69. Borno HT, Kuo Lin T, Odisho AY, Desai A, Koshkin V, Werner K, Legaspi N, Bucknor M, Bell A, Zhang S, Hope TA. PMID: 33247633.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    12. Outcomes With First-Line PD-1/PD-L1 Inhibitor Monotherapy for Metastatic Renal Cell Carcinoma (mRCC): A Multi-Institutional Cohort. Front Oncol. 2020; 10:581189. Barata P, Hatton W, Desai A, Koshkin V, Jaeger E, Manogue C, Cotogno P, Light M, Lewis B, Layton J, Sartor O, Basu A, Kilari D, Emamekhoo H, Bilen MA. PMID: 33194712.
      View in: PubMed   Mentions:
    13. PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancer. Future Oncol. 2021 Jan; 17(2):137-149. Huddart RA, Siefker-Radtke AO, Balar AV, Bilen MA, Powles T, Bamias A, Castellano D, Khalil MF, Van Der Heijden MS, Koshkin VS, Pook DW, Özgüroglu M, Santiago L, Zhong B, Chien D, Lin W, Tagliaferri MA, Loriot Y. PMID: 32938232.
      View in: PubMed   Mentions: 1     Fields:    
    14. Sequencing of PD-1/L1 Inhibitors and Carboplatin Based Chemotherapy for Cisplatin Ineligible Metastatic Urothelial Carcinoma. J Urol. 2021 02; 205(2):414-419. Wei XX, Werner L, Teo MY, Rosenberg JE, Koshkin VS, Grivas P, Szabados B, Morrison L, Powles T, Carril-Ajuria L, Castellano D, Velho PI, Hahn NM, McKay RR, Raggi D, Necchi A, Kanesvaran R, Alerasool P, Gaines J, Galsky M, Bellmunt J, Sonpavde G. PMID: 32935617.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    15. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020 06 20; 395(10241):1907-1918. Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, Shete S, Hsu CY, Desai A, de Lima Lopes G, Grivas P, Painter CA, Peters S, Thompson MA, Bakouny Z, Batist G, Bekaii-Saab T, Bilen MA, Bouganim N, Larroya MB, Castellano D, Del Prete SA, Doroshow DB, Egan PC, Elkrief A, Farmakiotis D, Flora D, Galsky MD, Glover MJ, Griffiths EA, Gulati AP, Gupta S, Hafez N, Halfdanarson TR, Hawley JE, Hsu E, Kasi A, Khaki AR, Lemmon CA, Lewis C, Logan B, Masters T, McKay RR, Mesa RA, Morgans AK, Mulcahy MF, Panagiotou OA, Peddi P, Pennell NA, Reynolds K, Rosen LR, Rosovsky R, Salazar M, Schmidt A, Shah SA, Shaya JA, Steinharter J, Stockerl-Goldstein KE, Subbiah S, Vinh DC, Wehbe FH, Weissmann LB, Wu JT, Wulff-Burchfield E, Xie Z, Yeh A, Yu PP, Zhou AY, Zubiri L, Mishra S, Lyman GH, Rini BI, Warner JL, COVID-19 and Cancer Consortium . PMID: 32473681.
      View in: PubMed   Mentions: 334     Fields:    Translation:HumansCellsPHPublic Health
    16. Randomized phase II trial of neoadjuvant everolimus in patients with high-risk localized prostate cancer. Invest New Drugs. 2019 06; 37(3):559-566. Koshkin VS, Mir MC, Barata P, Gul A, Gupta R, Stephenson AJ, Kaouk J, Berglund R, Magi-Galluzzi C, Klein EA, Dreicer R, Garcia JA. PMID: 31037562.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    17. Systematic Review: Targeting HER2 in Bladder Cancer. Bladder Cancer. 2019; 5(1):1-12. Koshkin VS, O’Donnell P, Yu EY, Grivas P. View Publication.
    18. Translational Cancer Research. The role of avelumab in advanced urothelial carcinoma in the context of a dynamic treatment landscape. 2018. Koshkin VS, Basu A, Grivas P. View Publication.
    19. Apalutamide in the treatment of castrate-resistant prostate cancer: evidence from clinical trials. Ther Adv Urol. 2018 Dec; 10(12):445-454. Koshkin VS, Small EJ. PMID: 30574205.
      View in: PubMed   Mentions:
    20. Transcriptomic and Protein Analysis of Small-cell Bladder Cancer (SCBC) Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target. Clin Cancer Res. 2019 01 01; 25(1):210-221. Koshkin VS, Garcia JA, Reynolds J, Elson P, Magi-Galluzzi C, McKenney JK, Isse K, Bishop E, Saunders LR, Balyimez A, Rashid S, Hu M, Stephenson AJ, Fergany AF, Lee BH, Haber GP, Dowlati A, Gilligan T, Ornstein MC, Rini BI, Abazeed ME, Mian OY, Grivas P. PMID: 30327311.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimalsCells
    21. Effect of Switching Systemic Treatment After Stereotactic Radiosurgery for Oligoprogressive, Metastatic Renal Cell Carcinoma. Clin Genitourin Cancer. 2018 10; 16(5):413-419.e1. Barata PC, Mendiratta P, Kotecha R, Gopalakrishnan D, Juloori A, Chao ST, Koshkin V, Ornstein M, Gilligan TD, Wood LS, Rini BI, Angelov L, Garcia JA. PMID: 30172552.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    22. HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer. J Clin Invest. 2018 08 01; 128(8):3333-3340. Alyamani M, Emamekhoo H, Park S, Taylor J, Almassi N, Upadhyay S, Tyler A, Berk MP, Hu B, Hwang TH, Figg WD, Peer CJ, Chien C, Koshkin VS, Mendiratta P, Grivas P, Rini B, Garcia J, Auchus RJ, Sharifi N. PMID: 29939161.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    23. Treatment selection for men with metastatic prostate cancer who progress on upfront chemo-hormonal therapy. Prostate. 2018 09; 78(13):1035-1041. Barata P, Emamekhoo H, Mendiratta P, Koshkin V, Tyler A, Ornstein M, Rini BI, Gilligan T, Kyriakopoulos C, Garcia JA. PMID: 29882332.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    24. Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook. Ther Clin Risk Manag. 2018; 14:1019-1040. Gopalakrishnan D, Koshkin VS, Ornstein MC, Papatsoris A, Grivas P. PMID: 29892196.
      View in: PubMed   Mentions:
    25. Perioperative chemotherapy for muscle-invasive bladder cancer: the importance of multidisciplinary management for evidence-based practice and transformative research. Transl Androl Urol. 2018 Jun; 7(3):504-507. Koshkin VS, Grivas P. PMID: 30050808.
      View in: PubMed   Mentions:
    26. Atezolizumab in Metastatic Urothelial Carcinoma Outside Clinical Trials: Focus on Efficacy, Safety, and Response to Subsequent Therapies. Target Oncol. 2018 06; 13(3):353-361. Barata PC, Gopalakrishnan D, Koshkin VS, Mendiratta P, Karafa M, Allman K, Martin A, Beach J, Profusek P, Tyler A, Wood L, Ornstein M, Gilligan T, Rini BI, Garcia JA, Grivas P. PMID: 29623487.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    27. Targeted Oncology. Future Directions of Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer. 2018. Koshkin VS, Grivas P. View Publication.
    28. Emerging Role of Immunotherapy in Advanced Urothelial Carcinoma. Curr Oncol Rep. 2018 04 11; 20(6):48. Koshkin VS, Grivas P. PMID: 29644490.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    29. Feasibility of Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer Patients With Diminished Renal Function. Clin Genitourin Cancer. 2018 08; 16(4):e879-e892. Koshkin VS, Barata PC, Rybicki LA, Zahoor H, Almassi N, Redden AM, Fergany AF, Kaouk J, Haber GP, Stephenson AJ, Ornstein MC, Gilligan T, Garcia JA, Rini BI, Grivas P. PMID: 29576445.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    30. Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma. J Immunother Cancer. 2018 01 29; 6(1):9. Koshkin VS, Barata PC, Zhang T, George DJ, Atkins MB, Kelly WJ, Vogelzang NJ, Pal SK, Hsu J, Appleman LJ, Ornstein MC, Gilligan T, Grivas P, Garcia JA, Rini BI. PMID: 29378660.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    31. Patient Characteristics, Treatment Patterns and Prognostic Factors in Squamous Cell Bladder Cancer. Clin Genitourin Cancer. 2018 04; 16(2):e437-e442. Zahoor H, Elson P, Stephenson A, Haber GP, Kaouk J, Fergany A, Lee B, Koshkin V, Ornstein M, Gilligan T, Garcia JA, Rini B, Grivas P. PMID: 29154041.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    32. Next-generation sequencing (NGS) of cell-free circulating tumor DNA and tumor tissue in patients with advanced urothelial cancer: a pilot assessment of concordance. Ann Oncol. 2017 Oct 01; 28(10):2458-2463. Barata PC, Koshkin VS, Funchain P, Sohal D, Pritchard A, Klek S, Adamowicz T, Gopalakrishnan D, Garcia J, Rini B, Grivas P. PMID: 28945843.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    33. Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis. Eur Urol Focus. 2019 03; 5(2):242-249. Necchi A, Mariani L, Lo Vullo S, Yu EY, Woods ME, Wong YN, Harshman LC, Alva A, Sternberg CN, Bamias A, Grivas P, Koshkin VS, Roghmann F, Dobruch J, Eigl BJ, Nappi L, Milowsky MI, Niegisch G, Pal SK, De Giorgi U, Recine F, Vaishampayan U, Berthold DD, Bowles DW, Baniel J, Theodore C, Ladoire S, Srinivas S, Agarwal N, Crabb S, Sridhar S, Golshayan AR, Ohlmann C, Xylinas E, Powles T, Rosenberg JE, Bellmunt J, van Rhijn B, Galsky MD, Hendricksen K, Young Academic Urologists-Urothelial Carcinoma Group-European Association of Urology and the Retrosp . PMID: 28753897.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    34. Cancer vaccines at the age of immune checkpoint inhibitors: reasonable approach as combination therapy in advanced urothelial carcinoma? Ann Oncol. 2017 04 01; 28(4):680-682. Grivas P, Koshkin VS, Pal SK. PMID: 28328001.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    35. Assessment of Imaging Modalities and Response Metrics in Ewing Sarcoma: Correlation With Survival. J Clin Oncol. 2016 Oct 20; 34(30):3680-3685. Koshkin VS, Bolejack V, Schwartz LH, Wahl RL, Chugh R, Reinke DK, Zhao B, O JH, Patel SR, Schuetze SM, Baker LH. PMID: 27573658.
      View in: PubMed   Mentions: 7     Fields:    
    36. Emerging therapeutics in refractory renal cell carcinoma. Expert Opin Pharmacother. 2016 Jun; 17(9):1225-32. Koshkin VS, Rini BI. PMID: 27112171.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    37. CAD-associated reader error in CT colonography. Acad Radiol. 2012 Jul; 19(7):801-10. Koshkin VS, Hinshaw JL, Wroblewski K, Dachman AH. PMID: 22537502.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    38. Caspase-mediated cell death predominates following engraftment of neural progenitor cells into traumatically injured rat brain. Brain Res. 2005 Dec 14; 1065(1-2):8-19. Bakshi A, Keck CA, Koshkin VS, LeBold DG, Siman R, Snyder EY, McIntosh TK. PMID: 16309635.
      View in: PubMed   Mentions: 25     Fields:    Translation:AnimalsCells
    Vadim's Networks
    Concepts (128)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (29)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version v3.0.0-839-g49dc76ac on PROFILES-PWEB01.

    Copyright © The Regents of the University of California